Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUOCINOLONE ACETONIDE vs ALA-SCALP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluocinolone acetonide is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cytokines (e.g., IL-1, IL-2, TNF-α). It also causes vasoconstriction and decreases cellular migration and immune response.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Atopic dermatitis,Seborrheic dermatitis,Psoriasis,Eczema,Lichen planus,Lichen simplex chronicus,Discoid lupus erythematosus,Otitis externa (otic solution),Corticosteroid-responsive dermatoses
Treatment of minimally to moderately thick actinic keratoses of the scalp (Grade 1 or 2) in immunocompetent patients,Off-label: other photosensitivity disorders
Topical: Apply thin film to affected area 2-4 times daily. Otic: 0.01% solution, 5 drops into ear canal twice daily. Intralesional: 3.3 mg/m L, 0.5-1 m L per injection every 1-2 weeks.
Topical application of a 5% solution to the scalp twice daily.
Terminal elimination half-life is approximately 1.3-1.5 hours following topical application; after systemic absorption (oral or injection), half-life is 1.5-2.0 hours, necessitating multiple daily dosing for sustained effect.
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Primarily hepatic via cytochrome P450 enzymes (CYP3A4) to inactive metabolites; also undergoes local metabolism in skin.
ALA is metabolized intracellularly via the heme biosynthesis pathway to protoporphyrin IX (Pp IX).
Primarily hepatic metabolism with renal excretion of metabolites (approximately 80% renal, 20% biliary/fecal). Less than 1% excreted unchanged in urine.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Approximately 90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin.
Not characterized; systemic levels are negligible after topical administration.
0.2-0.3 L/kg in adults; distributes extensively into tissues with higher concentrations in skin and synovial spaces after local administration.
Not applicable for topical route. If systemic exposure occurs, Vd is approximately 0.5 L/kg, consistent with distribution into total body water.
Topical: very low systemic absorption (approximately 1-2% through intact skin, up to 10-20% through damaged skin or with occlusion); oral: 20-40% due to first-pass metabolism; intra-articular: nearly 100% locally with minimal systemic exposure.
Topical: Systemic bioavailability is minimal (<1%) due to poor percutaneous absorption and rapid local metabolism.
No dose adjustment required for renal impairment as systemic absorption is minimal with topical use.
No dose adjustment required for renal impairment.
No dose adjustment required for hepatic impairment due to minimal systemic absorption.
No dose adjustment required for hepatic impairment.
Topical: Apply sparingly to affected area 2-3 times daily. Limit treatment duration to avoid systemic effects. Use lowest potency formulation; not recommended for prolonged use in children under 2 years.
Safety and efficacy in pediatric patients have not been established.
Use with caution due to increased skin fragility and potential for systemic absorption. Apply sparingly and limit duration. Monitor for cutaneous adverse effects.
No specific dose adjustment recommended; use with caution due to potential increased sensitivity.
No FDA boxed warnings specific to fluocinolone acetonide; however, systemic absorption of topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.
No FDA black box warning.
HPA axis suppression with prolonged use or application to large areas, occlusive dressings, or damaged skin.,Cushing's syndrome and hyperglycemia may occur with systemic absorption.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.,Local adverse reactions including burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Ophthalmic adverse effects: increased intraocular pressure, cataracts with periorbital use.,Not for ophthalmic use except as specifically indicated (e.g., otic solution).
Photosensitivity: avoid exposure to sunlight or bright indoor light (e.g., examination lamps, operating room lamps) for at least 40 hours post-application.,Application site reactions: severe stinging, burning, erythema, and edema may occur.,Use sun-protective measures (e.g., wide-brimmed hat, sunscreen) after treatment.,Do not apply to eyes or mucous membranes.
Hypersensitivity to fluocinolone acetonide or any component of the formulation,Untreated bacterial, fungal, viral (e.g., herpes simplex, vaccinia, varicella) or parasitic skin infections,Perioral dermatitis,Rosacea
Hypersensitivity to aminolevulinic acid or any component of the formulation,Cutaneous photosensitivity at wavelengths of 400-450 nm,Porphyria
No known food interactions. No dietary restrictions required.
No known food interactions. No dietary restrictions required.
Topical corticosteroids are generally considered low risk in pregnancy. First trimester: No evidence of increased congenital malformations in human studies. Second and third trimesters: Risk of fetal growth restriction and low birth weight with prolonged or high-dose use. Systemic absorption may occur with extensive application, occlusive dressings, or prolonged use. Risk of adrenal suppression in neonate if used near term in high doses.
No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.
Excretion in breast milk is unlikely after topical application, but systemic absorption could occur with extensive use. The M/P ratio is unknown. Caution is advised: avoid application to the breast area before nursing, and use the lowest effective dose for the shortest duration.
Minimal systemic absorption; unlikely to appear in breast milk. M/P ratio not established. Considered compatible with breastfeeding.
No specific dose adjustments required due to pharmacokinetic changes in pregnancy. Use the lowest effective potency and duration. Avoid excessive application, especially on large areas or under occlusive dressings.
No dosage adjustment required; pharmacokinetics unlikely altered due to topical route.
Fluocinolone acetonide is a potent corticosteroid for dermatologic use. Avoid prolonged use on face, intertriginous areas, or under occlusion due to increased systemic absorption and risk of atrophy. For scalp psoriasis, the oil-based solution or shampoo forms may improve compliance. Use limited quantities in children to minimize HPA axis suppression. Discontinue if irritation or sensitization occurs.
ALA-SCALP is a topical aminolevulinic acid preparation used for photodynamic therapy of actinic keratoses on the scalp. Must be applied by a healthcare professional. Avoid sun exposure to treated area for 48 hours post-application due to photosensitivity. Do not apply to eyes or mucous membranes. Lesions should be prepped by gentle removal of scales and crusts. Use with a compatible light source (blue light). Burning and stinging during light exposure is common; consider pain management strategies.
Apply a thin layer only to affected skin areas, avoiding healthy skin.,Do not use on broken skin, open wounds, or infections unless directed.,Wash hands after application unless treating hands.,Avoid contact with eyes and mucous membranes.,Do not cover treated areas with bandages or wraps unless instructed by your doctor.,Do not use for more than 2 consecutive weeks without re-evaluation.,Inform your doctor if you are pregnant, breastfeeding, or have diabetes.,Report any signs of skin thinning, stretch marks, or worsening rash.
This medication is applied by your doctor to treat precancerous spots on your scalp.,After application, you will need a special light treatment (photodynamic therapy).,Avoid sunlight and bright indoor light on the treated area for 48 hours after the procedure.,You may experience temporary redness, swelling, scaling, or discomfort at the treatment site.,Use sunscreen and protective clothing when going outdoors during the photosensitivity period.,Do not wash the treated area for at least 4 hours after the solution is applied.,Contact your doctor if you experience severe pain, blistering, or signs of infection.
"The combination of flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID), and fluocinolone acetonide, a corticosteroid, may lead to an increased risk of gastrointestinal (GI) adverse effects, including ulceration and bleeding, due to additive inhibition of prostaglandin synthesis. Additionally, corticosteroids can mask the signs of infection and inflammation, potentially delaying diagnosis of NSAID-induced GI injury. Concomitant use also increases the risk of renal impairment, fluid retention, and electrolyte disturbances, particularly in patients with pre-existing renal dysfunction or heart failure."
"Combined use of fluocinolone acetonide (a topical corticosteroid) and fluoxymesterone (an anabolic androgen) increases the risk of sodium and water retention due to their synergistic mineralocorticoid effects. This can lead to exacerbation of hypertension, edema, and potentially precipitate congestive heart failure in susceptible patients. The effect is dose-dependent and more pronounced with systemic absorption of the topical steroid (e.g., when applied to large areas or broken skin)."
"Icatibant, a bradykinin B2 receptor antagonist used for hereditary angioedema, may theoretically attenuate the anti-inflammatory effects of fluocinolone acetonide, a corticosteroid. Corticosteroids suppress inflammation partly by inhibiting bradykinin production and signaling; blocking bradykinin receptors could paradoxically reduce corticosteroid efficacy. However, direct clinical evidence for this interaction is lacking, and the theoretical risk of decreased therapeutic response to fluocinolone acetonide when used with icatibant remains unconfirmed."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUOCINOLONE ACETONIDE vs ALA-SCALP, answered by our medical review team.
FLUOCINOLONE ACETONIDE is a Topical Corticosteroid that works by Fluocinolone acetonide is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cytokines (e.g., IL-1, IL-2, TNF-α). It also causes vasoconstriction and decreases cellular migration and immune response.. ALA-SCALP is a Topical Corticosteroid that works by ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUOCINOLONE ACETONIDE and ALA-SCALP depend on the specific clinical indication. These are both Topical Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUOCINOLONE ACETONIDE is: Topical: Apply thin film to affected area 2-4 times daily. Otic: 0.01% solution, 5 drops into ear canal twice daily. Intralesional: 3.3 mg/m L, 0.5-1 m L per injection every 1-2 weeks.. The standard adult dose of ALA-SCALP is: Topical application of a 5% solution to the scalp twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLUOCINOLONE ACETONIDE and ALA-SCALP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLUOCINOLONE ACETONIDE is classified as Category A/B. Topical corticosteroids are generally considered low risk in pregnancy. First trimester: No evidence of increased congenital malformations in human studies. Second and third trimes. ALA-SCALP is classified as Category C. No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.